Share:
MILAN, Italy and NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced it will be presenting at several upcoming scientific congresses in May and June.
Details of the presentations are as follows:
American Society of Cell and Gene Therapy (ASGCT) 24
th
Annual Meeting, May 11-14, virtual
Title: Changes in the Tumor Microenvironment in Patients with Glioblastoma Multiforme Treated with IFN-a Immune Cell & Gene Therapy (TEM-GBM_001 Study)
Type: Oral presentation
2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, virtual
Title: A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study)